Drug Trial Radar · NCT07941362
177Lu-ACT319 in FAP Expressing Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Oct 25, 2026
Primary completion
Jul 31, 2029
Study completion Nov 2, 2031
Sponsor
- Lead sponsor
- Actithera INC.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last approximately 2 years. A separate group of patients with other FAP expressing solid tumor types will be evaluated by PET/CT or SPECT/CT imaging for the intensity of target expression.
Conditions
- FAP-expressing Solid Tumors
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Biliary Tract Carcinoma (BTC)
Interventions
177Lu-ACT319Drug
At Dose level 1
177Lu-ACT319Drug
At Dose Level 2
177Lu-ACT319Drug
At Dose Level 3
177Lu-ACT319Drug
At Dose Level 4
[18F]-FAPI-74 for imagingDrug
Low Dose \[18F\]-FAPI-74 for PET/CT imaging in Part 1B
177Lu-ACT319 for imagingDrug
Low Dose 177Lu-ACT319 for imaging in Part 1B
177Lu-ACT319 at RDEDrug
177Lu-ACT319 at Recommended Dose for Expansion
177Lu-ACT319 at RDE-1Drug
177Lu-ACT319 at one level lower than at Recommended Dose for Expansion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation (Part 1A)Time frame: First 42 days of Cycle 1
- Imaging/Dosimetry Sub-study (Part 1B)Time frame: 2 days post drug administration
- Dose optimization and expansion (Part 2A/2B)Time frame: Up to 12 months after the last treatment.
- Dose escalation (Part 1A)Time frame: Up to 24 months from the first treatment cycle administration.
- Imaging/Dosimetry Sub-study (Part 1B)Time frame: Up to 8 days.
- Dose escalation (Part 1A)Time frame: Up to 24 months from the first treatment cycle administration.
- Vital Signs: Change from baseline in systolic blood pressure (Part 1B)Time frame: Up to 8 days.
- Vital Signs: Change from baseline in diastolic blood pressure (Part 1B)Time frame: Up to 8 days.
- Vital Signs: Change from baseline in pulse rate (Part 1B)Time frame: Up to 8 days.
- Vital Signs: Change from baseline in respiratory rate (Part 1B)Time frame: Up to 8 days.
- Vital Signs: Change from baseline in body temperature (Part 1B)Time frame: Up to 8 days.
- ECGs: Change from baseline in ECG heart rate (Part 1B)Time frame: Up to 8 days.
- ECGs: Change from baseline in ECG PR interval (Part 1B)Time frame: Up to 8 days.
- ECGs: Change from baseline in ECG QRS duration (Part 1B)Time frame: Up to 8 days.
- ECGs: Change from baseline in ECG QT interval (Part 1B)Time frame: Up to 8 days.
- Imaging sub-study (Part 1B): Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to 8 days.
- ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1B)Time frame: Up to 8 days.
- Dose escalation (Part 1A)Time frame: First 42 days of Cycle 1
- Vital Signs: Change from baseline in systolic blood pressure (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- Vital Signs: Change from baseline in diastolic blood pressure (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- Vital Signs: Change from baseline in pulse rate (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- Vital Signs: Change from baseline in respiratory rate (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- Vital Signs: Change from baseline in body temperature (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- ECGs: Change from baseline in ECG heart rate (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- ECGs: Change from baseline in ECG PR interval (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- ECGs: Change from baseline in ECG QRS duration (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- ECGs: Change from baseline in ECG QT interval (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- ECOG: Change from baseline in ECOG performance status (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
- Dose Escalation (Part 1A): Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to 24 months from the first treatment cycle administration
- Dose optimization and expansion (Part 2A)Time frame: Up to 24 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.